Brief: Aptinyx Completes Enrollment In Phase 2 Study Of Nyx-458 In Cognitive Impairment Associated With Parkinson's Disease And Dementia With Lewy Bodies
U.S. RESEARCH ROUNDUP- Aptinyx, Rapid Micro Biosystems, Trinet Group
U.S. STOCKS ON THE MOVE-Forza X1, GlobalFoundries, Avient
U.S. STOCKS ON THE MOVE-AirSculpt, Honest, Acer Therapeutics
Aptinyx falls as pain drug fails another study
Brief: Aptinyx reports results from Phase 2B study of NYX-2925 in Fibromyalgia
Brief: Aptinyx Reports Second Quarter 2022 Financial Results And Recent Highlights
Brief: Aptinyx - On June 9, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing - SEC Filing
Aptinyx Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aptinyx Reports Q1 2022 Results
Aptinyx Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-ON24 Inc, Monarch Casino & Resort, NVIDIA Corp
U.S. STOCKS ON THE MOVE-Humana Inc, Netflix Inc, Xerox Holdings
U.S. STOCKS ON THE MOVE-Tesla Inc, ABB Ltd, Dow Inc
U.S. STOCKS ON THE MOVE-Tesla, ABB, Dow
SVB Leerink cuts PT for Aptinyx over pain drug data, trial delay
Brief: AptinyxHas Temporarily Paused Initiation Of Phase 2B Study For 150 Mg Dose Of NYX-783 In Patients With Post-Traumatic Stress Disorder
U.S. STOCKS ON THE MOVE-Roblox, U.S. insurers, gold miners
U.S. STOCKS ON THE MOVE-LXP Industrial, WD-40, Novavax